Panea et al. (2019)

Summary of novel genes

Entity Tier 1 genes Tier 2 genes
BL 4 36
--- config: sankey: showValues: true linkColor: target width: 600 height: 300 nodeAlignment: right prefix: '(' suffix: ' genes)' --- sankey-beta This study, New Tier 1, 4 New Tier 1, BL Tier 1, 4 This study, New Tier 2, 36 New Tier 2, BL Tier 2, 36 All other BL studies, BL Tier 1, 25 All other BL studies, BL Tier 2, 111

Novel genes reported in this study

Tier 1

New gene BL tier
BMP7 1
EIF4A1 1
EPPK1 1
HNRNPU 1

Tier 2

New gene BL tier Rating of reviewed variants QC outcome
ALPK2 2 ★ ☆ ☆ ☆ ☆ Fail
CD79B 2 ★ ★ ☆ ☆ ☆ Fail
CD83 2 ★ ★ ★ ☆ ☆ Pass
CTCF 2 ★ ☆ ☆ ☆ ☆ Fail
CXCR4 2 ★ ★ ★ ★ ☆ Pass
DNMT1 2 ★ ☆ ☆ ☆ ☆ Fail
DTX1 2 ★ ☆ ☆ ☆ ☆ Fail
ETS1 2 ★ ☆ ☆ ☆ ☆ Fail
FZD3 2 ★ ☆ ☆ ☆ ☆ Fail
HIST1H1C 2 ★ ★ ☆ ☆ ☆ Fail
HIST1H2AG 2 ★ ★ ☆ ☆ ☆ Fail
HIST1H2AM 2 ☆ ☆ ☆ ☆ ☆ Fail
HIST1H2BK 2 ★ ☆ ☆ ☆ ☆ Fail
HIST1H3D 2 ★ ★ ★ ☆ ☆ Pass
HIST1H3H 2 ☆ ☆ ☆ ☆ ☆ Fail
HIST1H3I 2 ★ ★ ★ ★ ☆ Pass
HIST1H3J 2 ☆ ☆ ☆ ☆ ☆ Fail
HIST1H4J 2 ★ ★ ★ ☆ ☆ Pass
IGLL5 2 ★ ★ ★ ★ ☆ Pass
IKZF3 2 ★ ★ ★ ☆ ☆ Pass
IRF8 2 ★ ★ ★ ★ ☆ Pass
KCNK10 2 ★ ★ ☆ ☆ ☆ Fail
MCL1 2 ★ ★ ★ ★ ☆ Pass
MME 2 ★ ☆ ☆ ☆ ☆ Fail
MTOR 2 ★ ☆ ☆ ☆ ☆ Fail
PABPC4L 2 ★ ★ ☆ ☆ ☆ Fail
PCDHA11 2 ★ ☆ ☆ ☆ ☆ Fail
PDZRN3 2 ★ ☆ ☆ ☆ ☆ Fail
PIK3R1 2 ★ ☆ ☆ ☆ ☆ Fail
PLCG2 2 ★ ★ ★ ☆ ☆ Pass
PXDNL 2 ★ ☆ ☆ ☆ ☆ Fail
RNF144B 2 ★ ★ ★ ☆ ☆ Pass
SNTB2 2 ★ ★ ☆ ☆ ☆ Fail
WDR7 2 ★ ★ ☆ ☆ ☆ Fail
WNK2 2 ★ ★ ★ ★ ☆ Pass
ZFP36L1 2 ★ ★ ★ ★ ☆ Pass

Details

Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A. Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt Lymphoma Subtypes.” Blood. https://doi.org/10.1182/blood.2019001880.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

In particular, let us know if you feel that an important citation is missing or if a paper has been cited incorrectly.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.